US Patent

US8945005 — Controlled activation ingestible identifier

Method of Use · Assigned to Proteus Digital Health Inc · Expires 2029-08-19 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a controlled activation ingestible identifier for use in pharmaceutical compositions, such as monitoring therapeutic regimen compliance.

USPTO Abstract

Controlled activation identifiers for use in ingestible compositions, such as pharma-informatics enabled compositions, are provided. The identifiers include a controlled activation element that provides for activation of the identifier in response to the presence of a predetermined stimulus at a target site of interest. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2167 — Abilify
U-2167 — Abilify
U-2167 — Abilify
U-2167 — Abilify
U-2167 — Abilify
U-2167 — Abilify

Patent Metadata

Patent number
US8945005
Jurisdiction
US
Classification
Method of Use
Expires
2029-08-19
Drug substance claim
No
Drug product claim
Yes
Assignee
Proteus Digital Health Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.